COMPARISON OF SPRINKLE VERSUS SYRUP FORMULATIONS OF VALPROATE FOR BIOAVAILABILITY, TOLERANCE, AND PREFERENCE

被引:41
作者
CLOYD, JC
KRIEL, RL
JONESSAETE, CM
ONG, BY
JANCIK, JT
REMMEL, RP
机构
[1] HENNEPIN CTY MED CTR, DEPT NEUROL, MINNEAPOLIS, MN 55415 USA
[2] GILLETTE CHILDRENS HOSP, ST PAUL, MN 55101 USA
关键词
D O I
10.1016/S0022-3476(05)82496-5
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
We compared a new coated-particle formulation of valproate (Depakote Sprinkle) capsules with valproic acid (Depakene) syrup for bioavailability, side effects, and patient and parent preference. Twelve children with epilepsy, aged 5 to 16 years, participated in this randomized, two-period, crossover study. They were assigned to a 7-day regimen with one formulation and then crossed over to the other; the drug was given every 12 hours. On day 7, blood samples collected during a 12-hour period were analyzed for the presence of valproate. At the study's end, parents and children were asked structured questions regarding formulation preference and adverse events. The extent of absorption from sprinkle equaled that from syrup (relative bioavailability = 1.02), but absorption was slower (time to maximum concentration = 4.2 vs 0.9 hour; p < 0.01). Fluctuations in serum concentrations were less with sprinkle (34.8% vs 62.3%; p < 0.01). Sprinkle was preferred by 9 of the 12 parents because of ease of administration, and by nine of the children because of improved palatability. We conclude that sprinkle may be substituted for syrup without changing the daily dose. Furthermore, sprinkle, because of its prolonged absorption, may be given every 12 hours to children receiving monotherapy. Compliance may be enhanced because of the more convenient dosing schedules and the high degree of patient and parent acceptance.
引用
收藏
页码:634 / 638
页数:5
相关论文
共 13 条
[1]  
ACARDI J, 1986, EPILEPSY CHILDREN, P319
[2]   ABSORPTION CHARACTERISTICS OF A NEW VALPROATE FORMULATION - DIVALPROEX SODIUM-COATED PARTICLES IN CAPSULES (DEPAKOTE SPRINKLE) [J].
CARRIGAN, PJ ;
BRINKER, DR ;
CAVANAUGH, JH ;
LAMM, JE ;
CLOYD, JC .
JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (08) :743-747
[3]  
CHUA AHC, 1980, J CLIN PHARMACOL, V20, P30
[4]   VALPROIC ACID PHARMACOKINETICS IN CHILDREN .2. DISCONTINUATION OF CONCOMITANT ANTIEPILEPTIC DRUG-THERAPY [J].
CLOYD, JC ;
KRIEL, RL ;
FISCHER, JH .
NEUROLOGY, 1985, 35 (11) :1623-1627
[5]   HOW OFTEN IS MEDICATION TAKEN AS PRESCRIBED - A NOVEL ASSESSMENT TECHNIQUE [J].
CRAMER, JA ;
MATTSON, RH ;
PREVEY, ML ;
SCHEYER, RD ;
OUELLETTE, VL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 261 (22) :3273-3277
[6]   PHARMACOLOGY OF VALPROIC ACID IN CHILDREN WITH SEVERE EPILEPSY - CLEARANCE AND HEPATOTOXICITY [J].
DODSON, WE ;
TASCH, V .
NEUROLOGY, 1981, 31 (08) :1047-1050
[7]   DIURNAL-VARIATION OF CARBAMAZEPINE AND CARBAMAZEPINE-10,11-EPOXIDE IN PLASMA AND SALIVA IN CHILDREN WITH EPILEPSY - A COMPARISON BETWEEN CONVENTIONAL AND SLOW-RELEASE FORMULATIONS [J].
EEGOLOFSSON, O ;
NILSSON, HL ;
TONNBY, B ;
ARVIDSSON, J ;
GRAHN, PA ;
GYLJE, H ;
LARSSON, C ;
NOREN, L .
JOURNAL OF CHILD NEUROLOGY, 1990, 5 (02) :159-165
[8]   EFFECT OF FOOD ON THE SERUM CONCENTRATION PROFILE OF ENTERIC-COATED VALPROIC ACID [J].
FISCHER, JH ;
BARR, AN ;
PALOUCEK, FP ;
DOROCIAK, JV ;
SPUNT, AL .
NEUROLOGY, 1988, 38 (08) :1319-1322
[9]  
Gibaldi M., 1982, PHARMACOKINETICS, P445
[10]   CLINICAL AND PHARMACOKINETIC OBSERVATIONS ON SODIUM VALPROATE - A 5-YEAR FOLLOW-UP-STUDY IN 100 CHILDREN WITH EPILEPSY [J].
HENRIKSEN, O ;
JOHANNESSEN, SI .
ACTA NEUROLOGICA SCANDINAVICA, 1982, 65 (05) :504-523